DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, Y.
Right arrow Articles by Yokoi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, Y.
Right arrow Articles by Yokoi, T.

Vol. 30, Issue 2, 155-160, February 2002

Formation of a Novel Quinone Epoxide Metabolite of Troglitazone with Cytotoxic to HepG2 Cells

Yui Yamamoto, Hiroshi Yamazaki, Tomoko Ikeda, Terumi Watanabe, Haruo Iwabuchi, Miki Nakajima, and Tsuyoshi Yokoi

Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan (Y.Y., H.Y., M.N., T.Y.); and Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Company Limited, Tokyo, Japan (T.I., T.W., H.I.)

Troglitazone, an oral antidiabetic drug, was reported to cause adverse hepatic effects in certain individuals, leading to its withdrawal from the market. After incubation of troglitazone (100 µM) with the human hepatoma cell line, HepG2 cells, and human primary hepatocytes for 48 to 72 h, an unknown peak was detected in the cell culture. The formation of this peak from troglitazone (100 µM) was also catalyzed by expressed CYP3A4, and further HPLC analysis revealed that there were three metabolites (metabolite A, B, and C) in the peak. The major metabolite, metabolite C (M-C) was identified as an epoxide of a quinone metabolite of troglitazone by comparison with a synthetic authentic standard using tandem mass spectrometry, 1H NMR, and 13C NMR analyses. The other two metabolites (M-A and M-B) were stereoisomers with the same molecular weight as M-C, probably produced from M-C by intramolecular rearrangement at the epoxide moiety. M-C showed a weak cytotoxicity in HepG2 cells at low concentrations, as assessed by the crystal violet-staining assay. Since epoxides are generally regarded as the chemically reactive species, M-C may play a role in idiosyncrasy of troglitazone hepatotoxicity via individual differences either in the formation or degradation of this metabolite.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
K. Mizuno, M. Katoh, H. Okumura, N. Nakagawa, T. Negishi, T. Hashizume, M. Nakajima, and T. Yokoi
Metabolic Activation of Benzodiazepines by CYP3A4
Drug Metab. Dispos., February 1, 2009; 37(2): 345 - 351.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Cardiovasc DisHome page
M. Collino, N. S.A. Patel, and C. Thiemermann
Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury
Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 179 - 197.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
Y. Kobayashi, C. Sridar, U. M. Kent, S. G. Puppali, J. M. Rimoldi, H. Zhang, L. Waskell, and P. F. Hollenberg
Structure-Activity Relationship and Elucidation of the Determinant Factor(s) Responsible for the Mechanism-Based Inactivation of Cytochrome P450 2B6 by Substituted Phenyl Diaziridines
Drug Metab. Dispos., December 1, 2006; 34(12): 2102 - 2110.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Toxicol. Sci., April 1, 2006; 90(2): 269 - 295.
[Abstract] [Full Text] [PDF]

Home page
 International Journal of ToxicologyHome page
G. Vansant, P. Pezzoli, R. Saiz, A. Birch, C. Duffy, F. Ferre, and J. Monforte
Gene Expression Analysis of Troglitazone Reveals Its Impact on Multiple Pathways in Cell Culture: A Case for In Vitro Platforms Combined with Gene Expression Analysis for Early (Idiosyncratic) Toxicity Screening
International Journal of Toxicology, March 1, 2006; 25(2): 85 - 94.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
R. Maniratanachote, K. Minami, M. Katoh, M. Nakajima, and T. Yokoi
Chaperone Proteins Involved in Troglitazone-Induced Toxicity in Human Hepatoma Cell Lines
Toxicol. Sci., February 1, 2005; 83(2): 293 - 302.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Zhang, M. Ogan, R. Gedamke, V. Roongta, R. Dai, M. Zhu, J. K. Rinehart, L. Klunk, and J. Mitroka
PROTEIN COVALENT BINDING OF MAXIPOST THROUGH A CYTOCHROME P450-MEDIATED ORTHO-QUINONE METHIDE INTERMEDIATE IN RATS
Drug Metab. Dispos., July 1, 2003; 31(7): 837 - 845.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Y. Watanabe, M. Nakajima, and T. Yokoi
Troglitazone Glucuronidation in Human Liver and Intestine Microsomes: High Catalytic Activity of UGT1A8 and UGT1A10
Drug Metab. Dispos., December 1, 2002; 30(12): 1462 - 1469.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.